embark: subset analysis of enzalutamide versus leuprolide in prostate cancer
Published 8 months ago • 323 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
6:35
talazoparib plus enzalutamide: talapro-2 results and subset analyses
-
5:16
enzamet: enzalutamide for metastatic prostate cancer
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:59
subtypes of prostate cancer and how they change our management
-
2:45
trial of lhrha, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
-
2:14
salv-enza: srt plus enzalutamide for psa recurrent high-risk prostate cancer delays psa progression
-
9:32
embark: changing the landscape in high-risk bcr prostate cancer
-
8:31
recent updates in prostate cancer: stampede, vision & profound
-
2:17
enzalutamide for biochemically recurrent prostate cancer | nejm
-
6:40
updated overall survival outcomes in enzamet (anzup 1304)
-
3:57
update on arches trial: implications for prostate cancer treatment
-
13:24
enzalutamide approved for prostate cancer with biochemical recurrence: stephen freedland, md
-
0:48
future research on srt plus enzalutamide for psa recurrent high-risk prostate cancer
-
1:50
dr. shore on the safety profiles of relugolix and leuprolide acetate in prostate cancer
-
1:30
terrain trial of enzalutamide versus bicalutamide for advanced prostate cancer
-
1:30
final os analysis from arches
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
4:53
asco: relugolix vs leuprolide for advanced prostate cancer